Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease

European Journal of Clinical Investigation

Volumn 35, Issue 9, 2005, Pages 537-545

  Wu, T C ^a,b   Leu, H B ^a,b   Lin, W T ^b   Lin, C P ^a,b   Lin, S J ^a,b   Chen, Jaw Wen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Coronary artery disease; High sensitivity C reactive protein; Matrix metalloproteinase; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; STROMELYSIN;

AGED; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL ANALYSIS; SYNDROME X;

AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERIOSCLEROSIS; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICROVASCULAR ANGINA; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 24144472308     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01548.x     Document Type: Article

References (25)

1. Hojo Y, Ikeda U, Katshuki TA, Mizuno O, Fujikawa H, Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002;161:185-92.
2. Davies MJ. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation 1998;97:2382-3.
3. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
4. Galis ZS, Sukhova GK, Larck MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
5. Wossner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
6. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
7. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DPV, Teepen H, van der Wal AC et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2, 9 in the human coronary artery. Atherosclerosis 2000;150:245-53.
8. Schoenhagen P, Vince DG, Ziada KM, Kapadia SR, Lauer MA, Crowe TD et al. Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am J Cardiol 2002;89:1354-9.
9. Beyzade S, Xhang S, Wong YK, Day IN, Eriksson P, Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 2003;41:2130-7.
10. Schwarz A, Haberbosch W, Tillmanns H, Gardemann A. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers 2002;18:121-8.
11. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
12. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
13. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
14. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schutt A, Rippin G et al. Regulation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:901-8.
15. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafher G, Tiret L et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-42.
16. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53.
17. Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002;62:337-2.
18. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72.
19. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lib Med 2001;39:380-4.
20. Pollanen PJ, Lehtimaki T, Ilveskoski E, Mikkelsson J, Kajander OA, Laippala P et al. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki sudden death study. Atherosclerosis 2002;164:329-35.
21. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572-9.
22. Shofuda K, Yasumitsu H, Nishihashi A, Miki K, Miyazaki K. Expression of three membrane-type matrix metalloproteinases in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. J Biol Chem 1997;272:9749-54.
23. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995;92:1393-8.
24. Son JW, Koh KK, Ann JY, Jin DK, Park GS, Kim DS et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82.
25. Death AK, Nakhla S, McGrath KCY, Martell S, Yue DK, Jessup W et al. Nitroglycerin up-regulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol 2002;39:1943-50.